Compare VanEck Rare Earth/Strategic Metals (REMX) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Rare Earth/Strategic Metals vs Tenet Healthcare Corporation — how do they compare? VanEck Rare Earth/Strategic Metals trades at $60.78 (market cap $1.75B), while Tenet Healthcare Corporation trades at $263.01 (market cap $20.98B). The key difference: Tenet Healthcare Corporation is far larger — about 12× VanEck Rare Earth/Strategic Metals's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Rare Earth/Strategic Metals for 50 Days and Tenet Healthcare Corporation for 15 Days on average.
| REMX | THC | |
|---|---|---|
Market Cap | $1.75B | $20.98B |
Volume | 930,523 | 428,008 |
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $280.77 |
52-Week Low | $60.58 | $161.37 |
Typical Hold Time | 50 Days | 15 Days |
Enterprise Value | — | $32.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $61.88, down 2.99% with bearish technical signals dominating. The ETF faces pressure from rare earth sector volatility and mixed performance among constituent companies. Technical indicators show oversold conditions with RSI readings below 23, while ADX signals strong bearish momentum. Recent news highlights sector challenges including China's export controls and shifting trade policies affecting critical minerals.
The rare earth sector faces structural headwinds despite strategic importance. While U.S. supply chain development offers long-term potential, high volatility (~50% annualized) and China concentration pose significant risks. Current technical weakness suggests cautious approach until fundamental catalysts emerge from constituent company developments or policy shifts.
Tenet Healthcare (THC) trades at $261.07, up 0.48% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 82.83% gross margins and consistent earnings beats, while trading at attractive valuations including a 10.07 P/E ratio. Recent news highlights upcoming Q3 2026 earnings on October 29th and positive coverage of the company's growth prospects despite surgical volume challenges.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and a $283.36 consensus target offering 8.5% upside. The healthcare provider shows improving profitability with net margins expected to reach 9.89% in 2026. Key risks include capital allocation sustainability and potential volatility around upcoming earnings, but the combination of value pricing and growth momentum supports a positive outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
